Diet- and valproate-induced transient hyperammonemia: Effect of L- carnitine

Pediatric Neurology

Volumn 16, Issue 4, 1997, Pages 301-305

  Gidal, Barry E ^a,b   Inglese, Christopher M ^b   Meyer, Jane F ^b   Pitterle, Michael E ^a   Antonopolous, Joann ^a   Rust, Robert S ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CARBAMAZEPINE; CARNITINE; VALPROIC ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HUMAN; HYPERAMMONEMIA; MALE; PRIORITY JOURNAL; PROTEIN DIET;

ADMINISTRATION, ORAL; ADOLESCENT; AMMONIA; ANTICONVULSANTS; CARNITINE; CHILD; DIET; EPILEPSY; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; VALPROIC ACID;

EID: 0030758525     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(97)00026-X     Document Type: Article

References (21)

1. Haidukewych D, John G, Zielinski JJ, Rodin EA. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit 1995;7:290-94.
2. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101: 782-5.
3. Coulter DL. Carnitine deficiency in epilepsy: Risk factors and treatment. J Child Neurol 1995;10:2S32-9.
4. Breningstall GN. Carnitine deficiency syndromes. Pediatr Neurol 1990;6:75-81.
5. Siliprandi N, Sartorelli L, Ciman M, De Lisa F. Carnitine: Metabolism and clinical chemistry. Clin Chim Acta 1989;183:3-12.
6. Koch KM, Wilensky AJ, Levy RH. Beta-oxidation of valproic acid. I. Effects of fasting and glucose in humans. Epilepsia 1989;30: 782-9.
7. Bohan TP, Millington DS. Valproyl-carnitine: A novel metabolite of valproic acid. Ann Neurol 1984;16:394.
8. Hirsch E, Marescaux C, Imler M, Warter JM. Sodium valproate induces a hyperammonemia of renal and hepatic origin depending on diet. In: Soeters PB, Wilson JHP Meijer AJ, Holm E, eds. Advances in ammonia metabolism and hepatic encephalopathy. Amsterdam: Elsevier Science Publishers BV, 1988;191-6.
9. Marini AM, Zaret BS, Beckner RR. Hepatic and renal contributions to valproate-induced hyperammonemia. Neurology 1988;38:365-71.
10. Martin G, Durozard D, Besson J, Baverel G. Effect of the antiepileptic drug sodium valproate on glutamine and glutamate metabolism in isolated human kidney tubules. Biochem Biophys Acta 1990; 1033:231-66.
11. Coude FX, Grimber G, Parvy P, Rabier D, Petit F. Inhibition of ureagenesis by valproate in rat hepatocytes: Role of N-acetyl-glutamate and acetyl-CoA. Biochem J 1983;316:233-6.
12. Laub MC. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986;27:55-9.
13. Zaccara G, Paganini M, Campostrini, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. Ther Drug Monit 1985;7:185-90.
14. De Vivo DC, Tien I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5:134-41.
15. Tien I, Xie ZW. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 1994;204:753-8.
16. Stephens JR, Levy RH. Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 1994;35:164-71.
17. Coulter DL, Allen RJ. Secondary hyperammonemia: A possible mechanism for valproate encephalopathy. Lancet 1980;1:1310-1.
18. Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr 1981;99:317-9.
19. Zaret BS, Beckner RR, Marini AM, Wagle W, Passarelli C. Sodium valproate induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982;32:206-8.
20. Zaccara G, Compostrini R, Paganini M, et al. Acute changes of blood ammonia may predict short-term effects of valproic acid. Neurology 1984;34:1519-21.
21. Beversdorf D, Allen C, Nordgren R. Valproate induced encephalopathy treated with carnitine in an adult [Letter]. J Neurol Neurosurg Psychiatry 1996;61:211.